Patents Examined by Dong Jiang
  • Patent number: 10738112
    Abstract: An anti-human IL-17A monoclonal antibody, the preparation method, and the use thereof are provided. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of inflammatory cytokines, such as IL-6 and the like by means of various cell lines induced by IL-17A, and can be used for preparing drugs for treating diseases involving immune-medicated inflammatory responses.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: August 11, 2020
    Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.
    Inventors: Chenghai Zhang, Lingqiao Zhu, Jinlin Guo, Jie Zhao, Honghai Gao, Lin Ma, Wei Dang, Yan Yang
  • Patent number: 10703799
    Abstract: The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: July 7, 2020
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Rudi Beyaert, Harald Braun, Bart Lambrecht, Hamida Hammad
  • Patent number: 10696747
    Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 30, 2020
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Peter Brauer, Siok Ping Yeo, Hwee Ching Tan, John Edward Connolly
  • Patent number: 10669324
    Abstract: The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 2, 2020
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Dominik Ter Meer, Thomas Pohl, Reno Winter, Uwe Jacob
  • Patent number: 10662245
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: May 26, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Patent number: 10646548
    Abstract: The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can further include other interleukins such as IL-1?, and IL 1? can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: May 12, 2020
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Andrew T. Gewirtz, Benyue Zhang
  • Patent number: 10640575
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 5, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 10618964
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. In a specific aspect, the present invention provides amino acid sequences and polypeptides that are capable of binding to two or more different antigenic determinants, epitopes, parts, domains of IL-6R, also referred to as “multiparatopic” (such as e.g. “biparatopic” or “triparatopic”, etc.) amino acid sequences and polypeptides.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: April 14, 2020
    Assignee: Ablynx N.V.
    Inventors: Veerle Compernolle, Francis Descamps
  • Patent number: 10611845
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: April 7, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Daniel Robert Hostetter, Stephen James Moore, Margaret Thy Luu Nguyen, Olga Vasiljeva, Jeanne Grace Flandez
  • Patent number: 10588969
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 17, 2020
    Assignee: Boston Pharmaceuticals, Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Patent number: 10584155
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 10, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • Patent number: 10583190
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 10, 2020
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Patent number: 10577415
    Abstract: IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: March 3, 2020
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Stephen John Demarest, Xiufeng Wu
  • Patent number: 10562967
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 18, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Patent number: 10544198
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang, Ganesh A. Kolumam, Wyne P. Lee
  • Patent number: 10526384
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: January 7, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Marlon Hinner, Laurent Audoly, Martin Huelsmeyer, Kristian Jensen, Gabriele Matschiner, Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer
  • Patent number: 10501536
    Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: December 10, 2019
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
  • Patent number: 10472416
    Abstract: The present invention provides pharmaceutical formulations for anti-IL-17 antibodies. These anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 12, 2019
    Assignee: Eli Lilly and Company
    Inventors: Vincent John Corvari, Barbara Ann Williams, Patrick Daniel Donovan, Aaron Paul Markham
  • Patent number: 10472423
    Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: November 12, 2019
    Assignee: Agency For Science, Technology and Research
    Inventors: Cheng-I Wang, Peter Brauer, Siok Ping Yeo, Hwee Ching Tan, John Edward Connolly
  • Patent number: 10472421
    Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 12, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Peter Brauer, Siok Ping Yeo, Hwee Ching Tan, John Edward Connolly